You can buy or sell AKCA and other stocks, options, ETFs, and crypto commission-free!
Akcea Therapeutics, Inc. engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. Read More It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Stock Price, News, & Analysis for Akcea Therapeutics
Akcea Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Ph...
Simply Wall StMar 1
Will Akcea Therapeutics, Inc.’s (NASDAQ:AKCA) Earnings Grow Over The Next Few Years?
Akcea Therapeutics, Inc.’s (NASDAQ:AKCA) most recent earnings announcement in December 2018 indicated company earnings became less negative compared to the previous year’s level as a result of recent tailwinds Investors may find it useful to understand how market analysts predict Akcea Therapeutics’s earnings growth trajectory over the next couple of years and whether the future looks brighter. I will be using net income excluding extraordinary items in order to exclude one-off volatility which I am not int...
The Motley FoolFeb 26
Akcea Therapeutics, Inc. (AKCA) Q4 2018 Earnings Conference Call Transcript
Akcea Therapeutics, Inc. (NASDAQ:AKCA) Q4 2018 Earnings Conference Call , 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good afternoon, and welcome to the Akcea Therapeutics Fourth Quarter and Year-end 2018 Conference Call. As a reminder, this call is being recorded. I will now turn the call over to Kathleen Gallagher, Akcea's Vice President of Corporate Communications and Investor Relations. Ms. Gallagher, please begin. Kathleen Gallag...
Expected May 2, After Hours